DK1003546T3 - Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon - Google Patents
Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferonInfo
- Publication number
- DK1003546T3 DK1003546T3 DK98933344T DK98933344T DK1003546T3 DK 1003546 T3 DK1003546 T3 DK 1003546T3 DK 98933344 T DK98933344 T DK 98933344T DK 98933344 T DK98933344 T DK 98933344T DK 1003546 T3 DK1003546 T3 DK 1003546T3
- Authority
- DK
- Denmark
- Prior art keywords
- treating patients
- patients affected
- consensus interferon
- disseminated sclerosis
- sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/911,893 US6013253A (en) | 1997-08-15 | 1997-08-15 | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1003546T3 true DK1003546T3 (da) | 2006-10-30 |
Family
ID=25431058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98933344T DK1003546T3 (da) | 1997-08-15 | 1998-07-15 | Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon |
Country Status (18)
Country | Link |
---|---|
US (1) | US6013253A (da) |
EP (1) | EP1003546B1 (da) |
JP (1) | JP3813440B2 (da) |
KR (1) | KR100415636B1 (da) |
CN (1) | CN1183963C (da) |
AT (1) | ATE338563T1 (da) |
AU (1) | AU741074B2 (da) |
CA (1) | CA2299361C (da) |
CY (1) | CY1107314T1 (da) |
DE (1) | DE69835823T2 (da) |
DK (1) | DK1003546T3 (da) |
ES (1) | ES2267188T3 (da) |
HK (1) | HK1030157A1 (da) |
HU (1) | HU229045B1 (da) |
IL (2) | IL134345A0 (da) |
PT (1) | PT1003546E (da) |
TW (1) | TW474817B (da) |
WO (1) | WO1999008702A1 (da) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US20030007972A1 (en) * | 1999-02-24 | 2003-01-09 | Edward Tobinick | Cytokine antagonists and other biologics for the treatment of bone metastases |
US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
WO2003049761A1 (en) * | 2000-12-08 | 2003-06-19 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
DE60232880D1 (de) | 2001-05-24 | 2009-08-20 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7230167B2 (en) | 2001-08-31 | 2007-06-12 | Syngenta Participations Ag | Modified Cry3A toxins and nucleic acid sequences coding therefor |
SI1471974T1 (sl) * | 2002-02-06 | 2007-12-31 | Ares Trading Sa | Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih |
US20040141947A1 (en) * | 2002-10-16 | 2004-07-22 | Hunter Samuel F. | Method for treatment of demyelinating central nervous system disease |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
AU2005211385B2 (en) * | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
DE102004008168B4 (de) * | 2004-02-19 | 2015-12-10 | Voxeljet Ag | Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung |
US7879320B2 (en) * | 2004-05-17 | 2011-02-01 | Ares Trading S.A. | Hydrogel interferon formulations |
EA010979B1 (ru) | 2004-06-01 | 2008-12-30 | Арес Трейдинг С.А. | Стабилизированные жидкие препаративные формы интерферона |
WO2005117948A1 (en) | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Method of stabilizing proteins |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
BG66458B1 (bg) | 2005-03-21 | 2014-10-31 | Иван Иванов | Средство за конкурентно инхибиране на ендогенен гама интерферон |
EP1901769A2 (en) * | 2005-05-02 | 2008-03-26 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
EP1917276B1 (en) | 2005-08-26 | 2018-03-21 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
CA2616479A1 (en) * | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
WO2007135172A2 (en) | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
WO2009080699A2 (en) * | 2007-12-20 | 2009-07-02 | Merck Serono S.A. | Peg-interferon-beta formulations |
US9359421B2 (en) | 2008-04-08 | 2016-06-07 | Tigo Gmbh | Suppressor of the endogenous interferon-gamma |
BG66517B1 (bg) | 2008-04-08 | 2016-02-29 | Tigo Gmbh | Супресор на ендогенния човешки гама - интерферон |
WO2013008102A2 (en) | 2011-07-14 | 2013-01-17 | R.E.D. Laboratories N.V../ S.A. | Methods and compositions for evaluating and/or treating chronic immune diseases |
HUE042463T2 (hu) | 2013-07-18 | 2019-07-29 | Univ Colorado Regents | Készítmény gyulladásos ízületi betegség kezelésére |
BG67190B1 (bg) | 2017-03-29 | 2020-11-16 | Tigo Gmbh | Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
CA2068320C (en) * | 1989-11-29 | 2000-10-17 | Robert Hageman | Production of recombinant human interleukin-1 inhibitor |
WO1991017184A1 (en) * | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
SG52537A1 (en) * | 1990-10-17 | 1998-09-28 | Amgen Inc | Methods and compositions for the treatment of cell proliferation disorders |
US5858355A (en) * | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
EP0575545B1 (en) * | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
DK0639079T3 (da) * | 1992-04-30 | 2000-06-13 | Amgen Inc | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme |
WO1994006457A1 (en) * | 1992-09-17 | 1994-03-31 | Synergen, Inc. | Pharmaceutical formulations of interleukin-1 inhibitors |
US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
EP0701563A4 (en) * | 1993-03-08 | 1997-07-02 | Univ Pittsburgh | GENE TRANSFER FOR THE TREATMENT OF CONNECTIVE TISSUES IN A HOST MAMMAL |
ATE226828T1 (de) * | 1993-03-19 | 2002-11-15 | Vacsyn Sa | Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
FR2706772A1 (en) * | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
WO1995021629A1 (en) * | 1994-02-08 | 1995-08-17 | Amgen Inc. | Oral delivery of chemically modified proteins |
-
1997
- 1997-08-15 US US08/911,893 patent/US6013253A/en not_active Expired - Lifetime
-
1998
- 1998-07-15 KR KR10-2000-7001097A patent/KR100415636B1/ko not_active IP Right Cessation
- 1998-07-15 CN CNB988081520A patent/CN1183963C/zh not_active Expired - Fee Related
- 1998-07-15 DE DE69835823T patent/DE69835823T2/de not_active Expired - Lifetime
- 1998-07-15 IL IL13434598A patent/IL134345A0/xx active IP Right Grant
- 1998-07-15 ES ES98933344T patent/ES2267188T3/es not_active Expired - Lifetime
- 1998-07-15 HU HU0002755A patent/HU229045B1/hu unknown
- 1998-07-15 JP JP2000509439A patent/JP3813440B2/ja not_active Expired - Lifetime
- 1998-07-15 PT PT98933344T patent/PT1003546E/pt unknown
- 1998-07-15 WO PCT/US1998/014622 patent/WO1999008702A1/en active IP Right Grant
- 1998-07-15 EP EP98933344A patent/EP1003546B1/en not_active Expired - Lifetime
- 1998-07-15 DK DK98933344T patent/DK1003546T3/da active
- 1998-07-15 AT AT98933344T patent/ATE338563T1/de active
- 1998-07-15 AU AU83006/98A patent/AU741074B2/en not_active Expired
- 1998-07-15 CA CA002299361A patent/CA2299361C/en not_active Expired - Fee Related
- 1998-07-29 TW TW087112465A patent/TW474817B/zh not_active IP Right Cessation
-
2000
- 2000-02-02 IL IL134345A patent/IL134345A/en not_active IP Right Cessation
-
2001
- 2001-02-16 HK HK01101141A patent/HK1030157A1/xx not_active IP Right Cessation
-
2006
- 2006-11-27 CY CY20061101704T patent/CY1107314T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0002755A2 (hu) | 2000-12-28 |
ES2267188T3 (es) | 2007-03-01 |
CY1107314T1 (el) | 2012-11-21 |
TW474817B (en) | 2002-02-01 |
JP2001515047A (ja) | 2001-09-18 |
CN1267225A (zh) | 2000-09-20 |
WO1999008702A1 (en) | 1999-02-25 |
US6013253A (en) | 2000-01-11 |
KR20010030563A (ko) | 2001-04-16 |
HK1030157A1 (en) | 2001-04-27 |
AU741074B2 (en) | 2001-11-22 |
JP3813440B2 (ja) | 2006-08-23 |
KR100415636B1 (ko) | 2004-01-24 |
CA2299361A1 (en) | 1999-02-25 |
EP1003546A1 (en) | 2000-05-31 |
PT1003546E (pt) | 2006-12-29 |
HUP0002755A3 (en) | 2001-11-28 |
DE69835823T2 (de) | 2007-08-09 |
AU8300698A (en) | 1999-03-08 |
CN1183963C (zh) | 2005-01-12 |
ATE338563T1 (de) | 2006-09-15 |
EP1003546B1 (en) | 2006-09-06 |
CA2299361C (en) | 2009-09-29 |
IL134345A0 (en) | 2001-04-30 |
DE69835823D1 (de) | 2006-10-19 |
HU229045B1 (en) | 2013-07-29 |
IL134345A (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1003546T3 (da) | Fremgangsmåde til behandling af patienter ramt af dissemineret sklerose ved anvendelse af konsensus interferon | |
NO965378D0 (no) | Pyrazolo- og pyrolopyridiner | |
EE9900481A (et) | Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks | |
DK0911033T3 (da) | Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis | |
DK0713701T3 (da) | 2-Brommelatonin til behandling af søvnforstyrrelser | |
ES2155817T1 (es) | Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo. | |
DK0867184T3 (da) | Anvendelse af tiagabin til behandling af søvnforstyrrelser | |
DK0880350T3 (da) | Behandling af dissemineret sklerose | |
DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
DE69905368T2 (de) | Oxydiertes thymosin beta 4 | |
EE9900036A (et) | Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks | |
IL161889A0 (en) | Method for treating diseases with omega interferon | |
ATE249835T1 (de) | Immunoregulator | |
EE9900477A (et) | Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks | |
DK0817646T3 (da) | Fremgangsmåder til behandling af inflammation og præparater derfor | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
DK1007040T3 (da) | Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom | |
PT900563E (pt) | Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas | |
LV10191A (lv) | Farmaceitiski lidzekli hepatita B virusa izraisito infekciju un slimibu arstesanai | |
DK0752884T3 (da) | Fremgangsmåde til behandling af auto-immune sygdomme ved anvendelse af type 1 interferoner | |
DK0862454T3 (da) | CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner | |
ATE270113T1 (de) | Zusammenstellungen zur verbesserten wundheilung | |
DK1019032T3 (da) | Fremgangsmåde til at forhindre misbrug af et transdermalt terapeutisk system | |
EA200300222A1 (ru) | Лечение гепатита c с помощью тимозина, интерферона и рибавирина | |
DK0900085T3 (da) | Behandling af overdreven aggression med olanzapin |